# Replicel Life Sciences Stock Probability Of Bankruptcy

RP Stock | CAD 0.06 0.00 0.00% |

RepliCel | Probability Of Bankruptcy |

**M**in 2024, whereas Market Cap is likely to drop slightly above 3.7

**M**in 2024.

## RepliCel Life Sciences Company odds of financial turmoil Analysis

RepliCel Life's Probability Of Bankruptcy is a relative measure of the likelihood of financial distress. For stocks, the Probability Of Bankruptcy is the normalized value of Z-Score. For funds and ETFs, it is derived from a multi-factor model developed by Macroaxis. The score is used to predict the probability of a firm or a fund experiencing financial distress within the next 24 months. Unlike Z-Score, Probability Of Bankruptcy is the value between 0 and 100, indicating the firm's actual probability it will be financially distressed in the next 2 fiscal years.

More About Probability Of Bankruptcy | All Equity Analysis

## Probability Of Bankruptcy | = | ## Normalized | | ## Z-Score |

## Current RepliCel Life Probability Of Bankruptcy | Over 86% |

Most of RepliCel Life's fundamental indicators, such as Probability Of Bankruptcy, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, RepliCel Life Sciences is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.

Our calculation of RepliCel Life probability of bankruptcy is based on Altman Z-Score and Piotroski F-Score, but not limited to these measures. To be applied to a broader range of industries and markets, we use several other techniques to enhance the accuracy of predicting RepliCel Life odds of financial distress. These include financial statement analysis, different types of price predictions, earning estimates, analysis consensus, and basic intrinsic valuation. Please use the options below to get a better understanding of different measures that drive the calculation of RepliCel Life Sciences financial health.

## RepliCel Probability Of Bankruptcy Driver Correlations

Understanding the fundamental principles of building solid financial models for RepliCel Life is extremely important. It helps to project a fair market value of RepliCel Stock properly, considering its historical fundamentals such as Probability Of Bankruptcy. Since RepliCel Life's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of RepliCel Life's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of RepliCel Life's interrelated accounts and indicators.

Click cells to compare fundamentals

The Probability of Bankruptcy SHOULD NOT be confused with the actual chance of a company to file for chapter 7, 11, 12, or 13 bankruptcy protection. Macroaxis simply defines Financial Distress as an operational condition where a company is having difficulty meeting its current financial obligations towards its creditors or delivering on the expectations of its investors. Macroaxis derives these conditions daily from both public financial statements as well as analysis of stock prices reacting to market conditions or economic downturns, including short-term and long-term historical volatility. Other factors taken into account include analysis of liquidity, revenue patterns, R&D expenses, and commitments, as well as public headlines and social sentiment.

Competition |

Based on the latest financial disclosure, RepliCel Life Sciences has a Probability Of Bankruptcy of 86%. This is 98.66% higher than that of the Biotechnology sector and 56.82% higher than that of the Health Care industry. The probability of bankruptcy for all Canada stocks is 115.92% lower than that of the firm.

## RepliCel Probability Of Bankruptcy Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses RepliCel Life's direct or indirect competition against its Probability Of Bankruptcy to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of RepliCel Life could also be used in its relative valuation, which is a method of valuing RepliCel Life by comparing valuation metrics of similar companies.RepliCel Life is currently under evaluation in probability of bankruptcy category among its peers.

## RepliCel Life Main Bankruptcy Drivers

2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||

Return On Assets | (5.94) | (3.75) | (6.88) | (0.93) | (1.08) | (1.14) | |

Asset Turnover | 0.7 | 0.84 | 0.6 | 0.44 | 1.23 | 0.92 | |

Net Debt | 425.4K | 41.7K | (186.9K) | (372.1K) | (334.9K) | (318.1K) | |

Total Current Liabilities | 1.6M | 2.2M | 1.7M | 2.1M | 2.4M | 2.5M | |

Non Current Liabilities Total | 3.4M | 3.2M | 5.8M | 4.6M | 5.3M | 5.6M | |

Total Assets | 505.5K | 421.0K | 591.8K | 798.2K | 718.4K | 898.5K | |

Total Current Assets | 233.2K | 185.7K | 393.0K | 635.7K | 731.0K | 793.7K | |

Total Cash From Operating Activities | (2.8M) | (765.2K) | (2.5M) | (1.4M) | (2.0M) | (2.1M) |

## RepliCel Fundamentals

Return On Asset | -1.02 | ||||

Profit Margin | 1.13 % | ||||

Operating Margin | (1.43) % | ||||

Current Valuation | 4.56 M | ||||

Shares Outstanding | 65 M | ||||

Shares Owned By Insiders | 62.69 % | ||||

Number Of Shares Shorted | 869 | ||||

Price To Earning | (1.05) X | ||||

Price To Sales | 10.11 X | ||||

Revenue | 353.74 K | ||||

Gross Profit | 353.74 K | ||||

EBITDA | (1.05 M) | ||||

Net Income | (69.29 K) | ||||

Cash And Equivalents | 1.16 M | ||||

Cash Per Share | 0.04 X | ||||

Total Debt | 40.96 K | ||||

Current Ratio | 2.09 X | ||||

Book Value Per Share | (0.07) X | ||||

Cash Flow From Operations | (1.99 M) | ||||

Short Ratio | 0.13 X | ||||

Earnings Per Share | (0.02) X | ||||

Target Price | 1.64 | ||||

Beta | 0.82 | ||||

Market Capitalization | 3.58 M | ||||

Total Asset | 798.22 K | ||||

Retained Earnings | (42.97 M) | ||||

Working Capital | (1.44 M) | ||||

Net Asset | 798.22 K |

## About RepliCel Life Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze RepliCel Life Sciences's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of RepliCel Life using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of RepliCel Life Sciences based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Please read more on our fundamental analysis page.
## Thematic Opportunities

### Explore Investment Opportunities

## Additional Tools for RepliCel Stock Analysis

When running RepliCel Life's price analysis, check to measure RepliCel Life's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy RepliCel Life is operating at the current time. Most of RepliCel Life's value examination focuses on studying past and present price action to predict the probability of RepliCel Life's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move RepliCel Life's price. Additionally, you may evaluate how the addition of RepliCel Life to your portfolios can decrease your overall portfolio volatility.